GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Does a Certified Review Committee Do?

In Japan, a certified review committee examines a regenerative medicine plan against the legal provision standards. It gives the clinic a written opinion on whether the treatment should be provided and what precautions are needed before the clinic submits its plan to the Minister of Health, Labour and Welfare 4980Plan. Its role continues after filing through plan-change reviews and opinions on safety and periodic reports 4980Plan. Its opinion is not product approval, a clinic ranking, or a personal treatment recommendation 4980. On 30 June 2026 the national registry listed 167 certified committees and 6,743 treatment plans (8 Class I, 2,463 Class II and 4,272 Class III), together with 85 research plans 001590173.pdf.

That filing total says nothing about whether treatment works. Product approval uses a separate system, and 26 regenerative medical products were listed as currently approved on 20 May 2026 000280868.pdf.

What Does a Certified Review Committee Do?

A committee opinion records its assessment of the plan and may identify precautions or concerns. Filing is a required administrative step, not government approval of efficacy or an unconditional licence to treat. Approval under the PMD Act applies to a named product with defined indications and conditions Index0003.

Scope: Japan, Act on the Safety of Regenerative Medicine (Act No. 85 of 2013). General information only, not personal medical advice.

What a Certified Committee Is

The formal name under Chapter III of the Safety Act is the Certified Committee for Regenerative Medicine. Certification includes requirements for competence and a fair review process. The clinic remains responsible for providing care; the committee assesses the plan and issues opinions 4980Plan.

The 30 June 2026 snapshot recorded 80 specified committees and 87 standard committees, 167 altogether 001590173.pdf. Class I and Class II plans require review by a specified certified committee. A standard committee may review Class III plans only 4980Plan.

Assessment of products for marketing approval falls under the Pharmaceuticals and Medical Devices Act, with scientific review supported by the PMDA, which is separate from the Safety Act filing route 0003Index. A plan that only uses an approved product within its approved use is handled under the product framework rather than the Safety Act filing route Index. The registration and compliance terminology sets out the distinction between filing and product approval, and the treatment process in Japan describes the filing steps in order.

The Two Committee Tiers

Plan risk class Committee tier required Practical effect
Class I regenerative medicine Specified certified committee; treatment may start only after an additional national check and waiting period Class I carries the strictest controls under the law
Class II regenerative medicine Specified certified committee Class II requires the higher-tier committee without the national waiting step used for Class I
Class III regenerative medicine Specified committee or standard committee qualified for Class III Techniques covered by the law that fall outside Class I and Class II

Of the 6,743 treatment plans on file on 30 June 2026, 2,463 were Class II (about 36.5%) and 4,272 were Class III (about 63.4%). Only 8 were Class I (about 0.1%) 001590173.pdf. These figures count filings. They do not count clinics or patients, and they do not measure successful outcomes. Risk class decides the review route; it does not indicate how well a treatment works 4980.

When a brochure names a committee, confirm its tier and compare it with the risk class stated in your provision plan 4980Plan.

What the Committee Reviews

The committee assesses documents rather than examining patients. For a patient reading the paperwork, the information can be grouped into six areas. This is a reading aid, not six statutory document categories 4980Plan:

  • Proposed technique and purpose, with the institution name and responsible physician
  • Cell source and processing method, including the processing site and applicable facility category
  • Dose, number of sessions, route of administration, and follow-up schedule
  • Eligibility and exclusion criteria that define who should not receive the intervention
  • Explanations of risks, alternatives, costs, and the right to withdraw given before consent
  • Record keeping, health monitoring during follow-up, and procedures for reporting problems

For cell-based plans, the applicable processing-facility route may involve notification, permission, or certification. Facility requirements are separate from the treatment decision Plan. For plans involving cultured cells, confirm whether processing occurs inside the clinic or at an external cell processing facility. Facility status relates to manufacturing oversight and does not demonstrate clinical benefit. The safety considerations in Japan explain why a filing record alone does not establish safety for a specific condition.

After the First Review

The committee continues to review plan changes and information reported by the provider. It does not monitor each patient directly 4980Plan.

  • Plan changes: changes other than those classified as minor require prior submission after committee review. Minor changes use a notification procedure Plan
  • Safety reporting: the provider reports disease, disability, death, or infection suspected to result from treatment. Where necessary, the committee gives an opinion on investigating the cause and measures to take. Separate reporting duties to the Minister also apply 4980
  • Periodic reporting: the provider reports on ongoing provision. The committee may advise precautions, improvements, or discontinuation when needed. Periodic reporting duties to the Minister also apply 4980
  • Government oversight: under Articles 31–33, the Minister may inspect the committee establisher, issue compliance or improvement orders, and revoke committee certification. These are government powers over the committee, not committee powers to license clinics 4980

The filing system depends on plan type. Non-research plans use the e-Regenerative Medicine system, while research plans under the same law use the Japan Registry of Clinical Trials (jRCT) Plan. Research registration records a study; it does not establish that an intervention works. The June 2026 tally listed 85 research plans separately from treatment plans 001590173.pdf.

What the Committee Does Not Do

  • Product approval is outside its role. Marketing approval is a separate decision for a named product with defined indications and conditions 0003
  • The committee reviews the proposed treatment, but its opinion alone does not establish benefit for a particular disease, stage, or age group. The 6,743 filings and 26 approved products come from separate systems with different dates and units, so no approval rate or likelihood of benefit can be calculated from those two totals 001590173.pdf000280868.pdf
  • Clinic ranking or provider selection is not part of its work 4980
  • The treating clinician must assess individual eligibility using the patient’s history and current condition. Committee review does not replace that consultation
  • Informed consent remains necessary. Patients still need a clear account of the exact intervention, planned follow-up, uncertain benefits, and possible harms before agreeing 4980Plan

Before You Decide

Use the written opinion when discussing the proposal with the clinic, alongside the checks involved in how to choose a hospital in Japan. The MHLW snapshot used here groups plans by risk class and treatment or research status. It contains no individual opinion dates, plan-version history, or patient outcomes. Those aggregate counts cannot establish whether a clinic’s current proposal matches its reviewed plan 001590173.pdf.

What to ask for

  1. The full plan number, risk class, clinic name, doctor in charge, and the date it was filed or updated
  2. The committee name and tier, the opinion date, which plan version it reviewed, and any conditions
  3. The exact treatment in that version: cell source, processing method, dose, sessions, route, follow-up
  4. The current consent forms for that version: risks, other options, costs, and what happens if something goes wrong
  5. Where you can check these documents in the public record and what has changed since the opinion date

Compare the proposed treatment with the reviewed plan. For example, if a brochure describes intravenous administration but the plan describes a local injection, ask which plan covers the proposed treatment and request the relevant opinion. This is a hypothetical document check, not a reported patient case. An opinion issued before a plan update is not automatically invalid: ask whether the change required further review and whether it occurred. The opinion date and filing date do not need to be identical Plan. General information organised by condition, such as this indications and contraindications overview, does not replace the exact plan for an individual case.

Be cautious when the plan number or opinion is withheld, when the opinion refers to another plan version, when cell descriptions omit source or processing details, when benefit is promised, or when payment is requested before the current documents have been provided Plan.

Short Answer

A certified review committee reviews the plan and issues opinions before filing and during ongoing provision. It can advise precautions, improvements, or discontinuation, but it does not grant product approval or guarantee results 4980. The 167 committees and 6,743 treatment plans recorded on 30 June 2026 describe the size of the system, not its effectiveness 001590173.pdf. Check the opinion against the treatment actually proposed, then discuss personal suitability with a qualified clinician.

Need help identifying which plan documents to request? Contact the patient support team with administrative questions. Personal suitability and treatment decisions require a clinician.

Ask About Plan Documents

References

  1. Act on the Safety of Regenerative Medicine (Act No. 85 of 2013)
  2. MHLW, Submission of provision plans
  3. MHLW, Implementation status as of 30 June 2026
  4. PMDA, ARM APAC Forum presentation, 20 May 2026
  5. MHLW, Regenerative medicine portal
  6. PMDA, Regenerative Medical Products (English)